Author: admin

Posted on

Tecan Integrates Agentic AI Into Its Introspect Lab Analytics Platform

Tecan reported the integration of agentic AI capabilities into its lab analytics platform Introspect, leveraging the NVIDIA BioNeMo Agent Toolkit, which enable AI agents to access scientific AI capabilities within the Introspect platform. The goal is to help laboratories to optimize operations.

According to Tecan, agentic AI will allow laboratories to move beyond traditional monitoring and reactive troubleshooting toward proactive actions that help prevent issues before they impact performance, quality, or scientific outcomes. Early access to the enhanced Introspect platform is available, with applications focused on pharmaceutical, biotechnology, and clinical laboratory environments.

A milestone in the collaboration announced in 2026, this agentic AI development demonstrates advancement of Tecan and Nvidia’s shared vision of enabling data-driven laboratories with AI-powered platforms designed to accelerate scientific discovery and improve laboratory productivity, notes a company spokesperson, who adds that agentic AI introduces a new paradigm for laboratory operations.

Rather than identifying problems after they occur, intelligent agents can continuously analyze laboratory data, workflows, and system performance to uncover hidden patterns that limit throughput, constrain scalability, or reduce operational efficiency, explains Mukta Acharya, executive vice president and head of the life sciences business division at Tecan. By transforming data into recommended actions, laboratories can accelerate decision-making, optimize resource utilization, and proactively improve overall productivity, she continues.

“Agentic AI has the potential to reshape how laboratories operate. By combining Tecan’s laboratory expertise with NVIDIA’s BioNeMo Agent Toolkit, we are enabling a new generation of intelligent laboratory solutions that can proactively support scientists, improve productivity, and help accelerate scientific outcomes,” says Acharya.

The work with Nvidia reportedly also focuses on the agentic guardrails required for the responsible and reliable deployment of AI in laboratory environments. These safeguards are designed to support transparency, reliability, and controlled automation, helping in the establishment of agentic AI as a technology to support key research and operational workflows.

The post Tecan Integrates Agentic AI Into Its Introspect Lab Analytics Platform appeared first on GEN – Genetic Engineering and Biotechnology News.

Posted on

Opinion: Banning gender-affirming care doesn’t protect children — it makes it harder to help them

I am a plastic surgeon who rebuilds faces after car accidents, helps cancer patients breathe, and restores infants’ ability to eat and smile. Yet what draws the most notice is my work transforming masculine features into feminine ones, and vice versa.

I am an outsider to the LGBTQIA+ community. I grew up in a conservative household in which discussions on sex and gender were taboo. But in residency, I saw patients in clinic every Monday with my attending, a cisgender, white, heterosexual male at least 60 years old, who had been providing surgical gender-affirming care for over 25 years. I saw how vulnerable the patients were, trapped in their bodies. I felt the weight they woke up with every day, trying to blend into the surrounding world of instantaneous judgements. And I saw the life-changing impact that surgery had.

Read the rest…

Posted on

Opinion: STAT+: The U.S.-China biotech crackdown may hurt the scientists America needs the most

I spent nearly two decades covering the biotech and pharma sector, first in Washington, D.C., and then in Beijing. My first story, published in 2007, covered the U.S. Food and Drug Administration’s decision to open its inaugural overseas office in China, a fast-emerging market I later covered for 12 years.

In that time, I saw a lot of discussion about what the growth of China’s biotech sector would mean for the U.S. Never have I been more concerned about that discourse than I am now.

In recent years, China has become a biotech innovator, accounting for 34% of roughly 14,088 new drugs in global clinical development, leading the United States’ 27%. China is now contributing to 40% of new drugs entering clinical stage each year, according to data provider Pharmcube. The company also noted that China’s out-licensing deals rose nearly tenfold from 2021 to 2025, to an record $137.7 billion. Amid all of this are concerns about stolen intellectual property and the China government’s state-run companies.

Continue to STAT+ to read the full story…

Posted on

STAT+: Sword Health contracted to provide AI-supported physical therapy for an entire country

Can artificial intelligence-powered care solve medical problems at national scale? A modest-sized European country is about to find out.

Portugal’s National Health Service this month inked a deal with digital health company Sword to make its physical therapy care available to the country’s entire population of 10 million people. After receiving a referral from a doctor, patients will receive unlimited access to Sword’s virtual therapy, which leans heavily on artificial intelligence to help guide and supervise care.

Founded a decade ago in Portugal, Sword Health has become one of the most prominent digital health companies offering chronic condition care in the United States. The new deal comes amid growing debate about how the government should support and pay for AI-based care stateside.

Continue to STAT+ to read the full story…

Posted on

STAT+: Investor Clive Meanwell on designing biotechs for population health, and AI’s role as a catalyst

At first, Pfizer’s offer to buy obesity startup Metsera was $7.3 billion. Then Novo Nordisk entered the fray with an unsolicited bid for $9 billion. Then it was a $10 billion counteroffer. A bidding war like that is an investor’s dream, and it happened to Clive Meanwell. Now, he’s betting on AI to help him do it again.

The onetime oncologist has worked in drug development and biotech investment for close to four decades, and he’s now investing in big ideas with firm Population Health Partners, where he’s chairman and partner. 

The firm looks for the biggest problems facing human health, problems that could yield a handsome return on investment when solved. “Then we ask the question, ‘Is there anywhere in the world a technology, or a new business model, or a molecule or two or three, or a class of drugs or diagnostics that could solve this problem?’” he said.

Continue to STAT+ to read the full story…

Posted on

STAT+: Moderna co-founder Kenneth Chien on the future of mRNA — and Moderna 

Among all the awards and mementos Moderna co-founder Kenneth Chien has accumulated over a 50-year career in science, one stands out for its sheer luxe: an Hermes belt.

It was a 2013 gift from Moderna CEO Stéphane Bancel, one of biotech’s more dapper CEOs, after Chien helped secure a large partnership between the then-tiny mRNA startup and the Swedish-British pharmaceutical giant AstraZeneca. 

The deal accelerated Moderna’s ascent, helping bring billions in funding and of course the life-saving mRNA Covid vaccines. But the actual medicines AstraZeneca planned to build through those deals — up to 40 mRNA-based drugs for cancer and cardiovascular disease — never materialized. 

Continue to STAT+ to read the full story…